Strait of Hormuz Shipping Crisis Deepens as Traffic Plunges Amid Iran-U.S. Tensions 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
Toyota Global Vehicle Sales Decline in March Amid RAV4 Transition and Middle East Slowdown 
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
Chinese Chip Stocks Surge on AI Boom and Domestic Tech Push 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
DeepSeek V4 Launch Signals China’s Growing AI Independence with Huawei Chips 
Google Secures Pentagon AI Deal for Classified Projects 
RALEIGH, N.C., Feb. 17, 2016 -- INC Research Holdings, Inc. (Nasdaq:INCR), a leading, global Phase I to IV contract research organization (CRO), today announced the launch of its Catalyst program to strengthen collaborations with clinical research sites worldwide, in turn enhancing patient focus and optimizing study delivery to drive improved predictability of clinical trials and reduce development timelines for biopharmaceutical customers worldwide.
INC’s Catalyst program includes two components — the Catalyst Site Network and the Catalyst Community — which focus on developing stronger collaborations with clinical research sites across the globe to drive continuous improvement and development of best practice in the delivery of clinical research. The program aligns closely with INC’s Trusted Process™ clinical development methodology, which focuses on reducing variability and increasing predictability to improve the conduct of clinical trials. INC’s Catalyst Site Network is a select group of high-performing sites strategically and therapeutically aligned both to its business and its customers, and the Catalyst Community is an online forum representing a broader range of sites to support ongoing collaboration and information exchange on the conduct of clinical trials, wider adoption of new methodologies and sharing of best practice.
“Sites play an essential role in bringing new therapies to market for patients,” said Clare Grace, PhD, Vice President, Site and Patient Access. “By involving them early on and making them a partner in the clinical development process, studies start more quickly and run more predictably, enabling INC to better deliver on the needs of our customers and ultimately accelerate the delivery of new therapies to patients. The launch of our Catalyst program underscores INC’s continued efforts and commitment to strengthening our connections with this critical stakeholder group to drive innovation in clinical research.”
INC Catalyst Sites will have the opportunity to participate in an increased volume of clinical trials, with a dedicated relationship manager supporting the site and facilitating optimal matching to protocols. Participation in INC’s Catalyst Site network is by invitation only and initial focus of the program is on oncology and vaccine sites in the United States and Asia/Pacific region, areas representing high-growth opportunity for the CRO industry and INC.
INC’s Catalyst Community will have access to many of the benefits enjoyed by the Company’s Catalyst Sites via profile-targeted content. Sites will be able to manage their profile, observe their study performance and gain insight into pipeline opportunities while contributing to new methodologies in development. The Catalyst Community is open to all sites and is planned for launch in the second quarter of 2016. Unlike site network programs that are oriented around preferred partnerships, INC Research’s Catalyst program has been developed to deliver meaningful benefits to all stakeholders in the clinical research setting with the ultimate goal of maintaining maximum choice and opportunity for patients.
Joining INC’s Catalyst Community
Clinical research sites interested in applying to become part of INC’s Catalyst Community should visit www.incresearch.com/catalystcommunity.
About INC Research
INC Research (Nasdaq:INCR) is a leading global contract research organization ("CRO") providing the full range of Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. Leveraging the breadth of our service offerings and the depth of our therapeutic expertise across multiple patient populations, INC Research connects customers, clinical research sites and patients to accelerate the delivery of new medicines to market. The Company was named “Best Contract Research Organization” in December 2015 by an independent panel for Scrip Intelligence and ranked “Top CRO to Work With” among large global CROs in the 2015 CenterWatch Global Investigative Site Relationship Survey. INC Research is headquartered in Raleigh, N.C., with operations across six continents and experience spanning more than 100 countries. For more information, please visit www.incresearch.com and connect with us on LinkedIn and Twitter @inc_research.
CONTACT: Investor Relations Contact: Ronnie Speight Vice President, Investor Relations Phone: +1 (919) 745-2745 Email: [email protected] Press/Media Contact: Lori Dorer Senior Director, Corporate Communications Phone: +1 (513) 763-1380 Email: [email protected]
